Product Information


Dynapar QPS

Dynapar QPS is India’s most advanced pain management solution with QPS technology which provides quicker and deeper / better penetration and is effective against all types of chronic pain.
  • More Information

The Research and Development department of Troikaa Pharmaceuticals Ltd. has worked relentlessly to overcome the problem of poor penetration and hence, has successfully developed a novel technology – the QPS Technology.

The acronym QPS stands for Quick Penetrating Solution. It is a novel patented drug delivery platform that provides quick and comprehensive penetration of the drug through the skin.

Two variants of diclofenac QPS have been developed, namely, Dynapar QPS and Dynapar QPS Plus. Both Dynapar QPS and Dynapar QPS Plus are based on the same path breaking drug delivery platform. They provide freedom to select an appropriate formulation depending upon the physician’s clinical judgment as well as the patient’s preference to counter irritants.

Medical uses:

Dynapar QPS contains a non-steroidal anti-inflammatory (NSAID) drug used to treat mild to moderate pain and inflammation, particularly musculoskeletal pain. It is the world’s first transdermal preparation of diclofenac solution, providing superior pain relief after topical application by enhancing the penetration of diclofenac through the skin. The preparation is backed by proof of concept pharmacokinetic studies, as well as clinical trials. Since Dynapar QPS provides prompt pain relief upon being applied to any inflamed area (knee, back, elbow, neck, ankle, etc.), it minimises or eliminates the patient’s requirement of oral pain killers. Dynapar QPS, therefore, brings a paradigm shift in the management of musculoskeletal pain.

How it works:

Dynapar QPS is a quick penetrating solution of diclofenac, based on the QPS Novel Drug Delivery Platform. The QPS formulation enables quick absorption of diclofenac at the site of topical application, leading to high levels of the drug in the tissue surrounding the site of application. Better transdermal penetration is achieved through enhanced paracellular movement of the QPS base, within which, diclofenac is solubilised. The mechanism of penetration of QPS is paracellular transport across the stratum corneum which provides enhanced penetration into the skin. QPS technology utilises a unique base in which the drug is solubilised. The base is absorbed into the skin, carrying the solubilised drug through the barrier of the stratum corneum. Being non-aqueous, the QPS base passes through the paracellular lipid matrix, thereby, providing enhanced penetration. The excipient, and its proportion in the QPS base, has been optimised after a series of pharmacokinetic studies. The optimised formulation provides adequate transdermal penetration.


When Dynapar QPS is applied locally, the active substance (diclofenac) is well penetrated and absorbed through the skin. The time to reach maximum concentration of diclofenac after local application is approximately 5 hours. Diclofenac is more than 99% bound to human serum proteins, primarily to albumin.

Dosage and administration:

Dynapar QPS delivers 4 mg of diclofenac in each actuation (pump stroke). Dynapar QPS Plus delivers 2 mg of diclofenac in each actuation. Each pump stroke delivers 0.1ml of the solution. The recommended dose of Dynapar QPS and Dynapar QPS Plus is 4 sprays 4 times daily.



    • Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDs.
    • Hypersensitivity to diclofenac, acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs) or any associated excipient
    • Children and adolescents less than 14 years of age.
    • During the last trimester of pregnancy.

    Undesirable effects

    In phase III clinical trial of Dynapar QPS, no adverse event was reported. However topical application of diclofenac may be associated with local adverse effects at the site of application. Skin: Local irritation, pruritus, rash, eczema, erythema (including in rare cases erythema bullosum), urticaria, contact dermatitis, contact dermatitis with vesicles, etc. Isolated cases of generalised skin rash, hypersensitivity reactions such as angioedema, anaphylactic reactions and photosensitivity reactions have been reported in patients using topical NSAID preparations.



    The low systemic availability of diclofenac from DYNAPAR QPS makes overdose very unlikely. However, undesirable effects, similar to those observed following overdose of diclofenac tablets, can be expected if DYNAPAR QPS is inadvertently ingested (1 bottle of 15 / 30 ml contains the equivalent of 300 – 1200 mg of diclofenac sodium). In the event of accidental ingestion, resulting in significant systemic adverse effects, general therapeutic measures, normally adopted to treat poisoning with non- steroidal anti-inflammatory medicines should be used. Management of overdosage with NSAIDs essentially consists of supportive and symptomatic measures. Gastric decontamination and the use of activated charcoal should be considered. Supportive and symptomatic treatment should be given for complications such as hypotension, renal failure, convulsions, gastro-intestinal irritation, and respiratory depression; specific therapies such as forced diuresis, dialysis or haemoperfusion are probably of no help in eliminating NSAIDs due to their high rate of protein binding and extensive metabolism.


    Drug-drug interactions

    When used as per recommended dosage, the systemic availability of diclofenac from DYNAPAR QPS is very low as compared to oral formulation of diclofenac. Hence, the risk of drug interactions with other oral medicinal products is reduced. Concurrent acetylsalicylic acid or other NSAIDs may result in an increased incidence of adverse reaction.